Small-molecule coh-sr4 inhibits adipocyte differentiation via ampk activation

International Journal of Molecular Medicine

Volumn 31, Issue 5, 2013, Pages 1166-1176

  Figarola, James L ^a   Rahbar, Samuel ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

3T3 L1 adipocytes; AMPK; Cell cycle arrest; COH SR4; MTOR; Obesity

Indexed keywords

ANTIOBESITY AGENT; CCAAT ENHANCER BINDING PROTEIN ALPHA; COH SR4; CYCLIN A; CYCLIN B1; CYCLIN DEPENDENT KINASE 2; FAS ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN P27; PROTEIN P70; S6 KINASE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TUBERIN; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CYTOTOXICITY TEST; DRUG CYTOTOXICITY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID STORAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION;

3T3-L1 CELLS; ADIPOCYTES; ADIPOGENESIS; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; APOPTOSIS; CATALYTIC DOMAIN; CELL DIFFERENTIATION; CELL SURVIVAL; CLONE CELLS; ENZYME ACTIVATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICE; MITOSIS; MULTIPROTEIN COMPLEXES; PHENYLUREA COMPOUNDS; RNA, SMALL INTERFERING; SMALL MOLECULE LIBRARIES; TOR SERINE-THREONINE KINASES;

EID: 84876141146     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1313     Document Type: Article

References (50)

1. Grundy SM: Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 89: 2595-2600, 2004.
2. Khandekar MJ, Cohen P and Spiegelman BM: Molecular mechanisms of cancer development in obesity. Nat Rev Cancer 11: 886-895, 2011.
3. Jo J, Gavrilova O, Pack S, Jou W, Mullen S, Sumner AE, Cushman SW and Periwal V: Hypertrophy and/or hyperplasia: Dynamics of adipose tissue growth. PLoS Comput Biol 5: E1000324, 2009.
4. Pilch PF and Bergenhem N: Pharmacological targeting of adipocytes/fat metabolism for treatment of obesity and diabetes. Mol Pharmacol 70: 779-785, 2006.
5. Rosen ED and MacDougald OA: Adipocyte differentiation from the inside out. Nat Rev Mol Cell Biol 7: 885-896, 2006.
6. Lowe CE, O'Rahilly S and Rochford JJ: Adipogenesis at a glance. J Cell Sci 124: 2681-2686, 2011.
7. Tang QQ, Otto TC and Lane MD: Mitotic clonal expansion: A synchronous process required for adipogenesis. Proc Natl Acad Sci USA 100: 44-49, 2003.
8. Fajas L: Adipogenesis: A cross-talk between cell proliferation and cell differentiation. Ann Med 35: 79-85, 2003.
9. Farmer SR: Transcriptional control of adipocyte formation. Cell Metab 4: 263-273, 2006.
10. Hardie DG: AMP-activated protein kinase: An energy sensor that regulates all aspects of cell function. Genes Dev 25: 1895-1908, 2011.
11. Carling D, Mayer FV, Sanders MJ and Gamblin SJ: AMP-activated protein kinase: Nature's energy sensor. Nat Chem Biol 7: 512-518, 2011.
12. Steinberg GR and Kemp BE: AMPK in health and disease. Physiol Rev 89: 1025-1078, 2009.
13. Villena JA, Viollet B, Andreelli F, Kahn A, Vaulont S and Sul HS: Induced adiposity and adipocyte hypertrophy in mice lacking the AMP-activated protein kinase-alpha2 subunit. Diabetes 53: 2242-2249, 2004.
14. Zhang W, Zhang X, Wang H, et al: AMP-activated protein kinase α1 protects against diet-induced insulin resistance and obesity. Diabetes 61: 3114-3125, 2012.
15. Habinowski SA and Witters LA: The effects of AICAR on adipocyte differentiation of 3T3-L1 cells. Biochem Biophys Res Commun 286: 852-856, 2001.
16. Giri S, Rattan R, Haq E, Khan M, Yasmin R, Won JS, Key L, Singh AK and Singh I: AICAR inhibits adipocyte differentiation in 3T3L1 and restores metabolic alterations in diet-induced obesity mice model. Nutr Metab 3: 31, 2006.
17. Zhou Y, Wang D, Zhu Q, Gao X, Yang S, Xu A and Wu D: Inhibitory effects of A-769662, a novel activator of AMP-activated protein kinase, on 3T3-L1 adipogenesis. Biol Pharm Bull 32: 993-998, 2009.
18. Vingtdeux V, Chandakkar P, Zhao H, Davies P and Marambaud P: Small-molecule activators of AMP-activated protein kinase (AMPK), RSVA314 and RSVA405, inhibit adipogenesis. Mol Med 17: 1022-1030, 2011.
19. Figarola JL, Weng Y, Lincoln C, Horne D and Rahbar S: Novel dichlorophenyl urea compounds inhibit proliferation of human leukemia HL-60 cells by inducing cell cycle arrest, differentiation and apoptosis. Invest New Drugs 30: 1413-1425, 2012.
20. Singhal SS, Figarola J, Singhal J, et al: 1,3-Bis(3,5-dichlorophenyl) urea compound 'COH-SR4' inhibits proliferation and activates apoptosis in melanoma. Biochem Pharmacol 84: 1419-1427, 2012.
21. Vermeulen K, Van Bockstaele DR and Berneman ZN: The cell cycle: A review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36: 131-149, 2003.
22. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C and Blenis J: MTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 24: 200-216, 2004.
23. Laplante M and Sabatini DM: MTOR signaling in growth control and disease. Cell 149: 274-293, 2012.
24. Zoncu R, Efeyan A and Sabatini DM: MTOR: From growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12: 21-35, 2011.
25. Ma XM and Blenis J: Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10: 307-318, 2009.
26. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE and Shaw RJ: AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30: 214-226, 2008.
27. Inoki K, Zhu T and Guan KL: TSC2 mediates cellular energy response to control cell growth and survival. Cell 115: 577-590, 2003.
28. Sarbassov DD, Guertin DA, Ali SM and Sabatini DM: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101, 2005.
29. Fogarty S and Hardie DG: Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim Biophys Acta 1804: 581-591, 2009.
30. Menendez JA and Lupu R: Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7: 763-777, 2007.
31. Hardie DG: Sensing of energy and nutrients by AMP-activated protein kinase. Am J Clin Nutr 93: 891S-896S, 2011.
32. Qiu BY, Turner N, Li YY, et al: High-throughput assay for modulators of mitochondrial membrane potential identifies a novel compound with beneficial effects on db/db mice. Diabetes 59: 256-265, 2010.
33. Chen S, Li Z, Li W, Shan Z and Zhu W: Resveratrol inhibits cell differentiation in 3T3-L1 adipocytes via activation of AMPK. Can J Physiol Pharmacol 89: 793-799, 2011.
34. Lee YS, Kim WS, Kim KH, et al: Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 55: 2256-2264, 2006.
35. Rattan R, Giri S, Singh AK and Singh I: 5-Aminoimidazole-4-carboxamide-1- beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem 280: 39582-39593, 2005.
36. Inoki K, Kim J and Guan KL: AMPK and mTOR in cellular energy homeostasis and drug targets. Annu Rev Pharmacol Toxicol 52: 381-400, 2012.
37. Laplante M and Sabatini DM: An emerging role of mTOR in lipid biosynthesis. Curr Biol 19: R1046-R1052, 2009.
38. Polak P, Cybulski N, Feige JN, Auwerx J, Rüegg MA and Hall MN: Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration. Cell Metab 8: 399-410, 2008.
39. Zhang HH, Huang J, Düvel K, et al: Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. PLoS One 4: E6189, 2009.
40. Dowling RJ, Topisirovic I, Alain T, et al: MTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science 328: 1172-1176, 2010.
41. Culjkovic B, Topisirovic I, Skrabanek L, Ruiz-Gutierrez M and Borden KL: EIF4E is a central node of an RNA regulon that governs cellular proliferation. J Cell Biol 175: 415-426, 2006.
42. Calkhoven CF, Muller C and Leutz A: Translational control of C/EBPalpha and C/EBPbeta isoform expression. Genes Dev 14: 1920-1932, 2000.
43. Rosen ED, Hsu C-H, Wang X, Sakai S, Freeman MW, Gonzalez FJ and Spiegelman BM: C/EBPalpha induces adipogenesis through PPARgamma: A unified pathway. Genes Dev 16: 22-26, 2002.
44. Yeh WC, Bierer BE and McKnight SL: Rapamycin inhibits clonal expansion and adipogenic differentiation of 3T3-L1 cells. Proc Natl Acad Sci USA 92: 11086-11090, 1995.
45. Hashemolhosseini S, Nagamine Y, Morley SJ, Desrivières S, Mercep L and Ferrari S: Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem 273: 14424-14429, 1998.
46. Cho HJ, Park J, Lee HW, Lee YS and Kim JB: Regulation of adipocyte differentiation and insulin action with rapamycin. Biochem Biophys Res Commun 321: 942-948, 2004.
47. El-Chaar D, Gagnon A and Sorisky A: Inhibition of insulin signaling and adipogenesis by rapamycin: Effect on phosphorylation of p70 S6 kinase vs eIF4E-BP1. Int J Obes Relat Metab Disord 28: 191-198, 2004.
48. Kimura N, Tokunaga C, Dalal S, et al: A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway. Genes Cells 8: 65-79, 2003.
49. Chiang PC, Lin SC, Pan SL, Kuo CH, et al: Antroquinonol displays anticancer potential against human hepatocellular carcinoma cells: A crucial role of AMPK and mTOR pathways. Biochem Pharmacol 79: 162-171, 2010.
50. Kalender A, Selvaraj A, Kim SY, et al: Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 11: 390-401, 2010.